Quick Answer
Cytek Biosciences, Inc. reported Gross Profit of $104.46 million for fiscal year 2025.
Cytek Biosciences, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $104.46M | -6.0% |
| 2024 | $111.11M | +1.5% |
| 2023 | $109.43M | +8.4% |
| 2022 | $100.97M | +27.6% |
| 2021 | $79.14M | +53.1% |
| 2020 | $51.71M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.55M | -5.0% | +15.4% |
| June 30, 2025 | $23.87M | -6.2% | +18.4% |
| March 31, 2025 | $20.16M | -12.4% | -30.5% |
| September 30, 2024 | $29.00M | +6.7% | +14.0% |
| June 30, 2024 | $25.44M | -9.7% | +10.5% |
| March 31, 2024 | $23.01M | +9.4% | -15.3% |
| September 30, 2023 | $27.18M | +1.2% | -3.5% |
| June 30, 2023 | $28.16M | +14.7% | +33.9% |
- Cytek Biosciences, Inc. showed a decrease of -6.0% in Gross Profit compared to the prior fiscal year.
- Over the 2020–2025 period, Cytek Biosciences, Inc.’s gross profit has grown by 102.0% (from $51.71 million to $104.46 million).
- The most recent figure is from Cytek Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: